Harmony Biosciences Faces Patent Setback: Analyst Downgrades Stock
Truist analyst downgrades Harmony Biosciences to Hold after unfavorable trial signals on WAKIX patent challenge, warning of early generic entry risk and major franchise threat.
Already have an account? Sign in.